Mundipharma
Simon Evans is a seasoned professional in pricing strategy and commercial management, currently serving as Senior Pricing Manager, Global Commercial at Mundipharma since September 2015. In this role, Simon leads global pricing software initiatives, oversees pricing governance, and provides strategic expertise for innovative product launches. Prior positions at Mundipharma include Strategic Pricing Lead Europe, where Simon coordinated pricing activities across numerous countries, and Strategic Pricing Manager, focusing on asset pricing strategies. Simon started their career at Innovex as a Medical Salesperson, later becoming a Senior Account Executive at Napp Pharmaceuticals, where responsibilities expanded to commercial management. Simon holds a Bachelor of Science (BSc) in Medical Microbiology and Bacteriology from The University of Edinburgh.
This person is not in any teams
Mundipharma
5 followers
The Mundipharma global network of independent associated companies shares a common purpose to identify and accelerate the development of meaningful medicines that add value for patients and healthcare providers around the globe. Founded in the US by two physicians in 1952 and still privately owned, the network has a presence in over 120 countries. In Europe, the network employees more than 2,000 employees from R&D to manufacturing & supply and commercial, and with revenues in excess of €1 billion. At Mundipharma we strive for one high performing and learning environment where individuals can make a real difference. We have a strong track record of building successful alliances to license, develop and market medicines that improve patients’ lives, while also providing attractive options to financially constrained healthcare systems. Consistent with our entrepreneurial heritage, we like to think that we see what others don’t by challenging conventional wisdom and asking different and challenging questions. By working in partnership with all our stakeholders, the Mundipharma network develops medicines that create value for patients, payers and wider healthcare systems. We have built a European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as diabetes, respiratory, oncology, pain and biosimilars.